MX2009002707A - Azole nucleosides and use as inhibitors of rna and dna varial polymerases. - Google Patents

Azole nucleosides and use as inhibitors of rna and dna varial polymerases.

Info

Publication number
MX2009002707A
MX2009002707A MX2009002707A MX2009002707A MX2009002707A MX 2009002707 A MX2009002707 A MX 2009002707A MX 2009002707 A MX2009002707 A MX 2009002707A MX 2009002707 A MX2009002707 A MX 2009002707A MX 2009002707 A MX2009002707 A MX 2009002707A
Authority
MX
Mexico
Prior art keywords
heterocyclo
aryl
cycloalkyl
alkyl
cycloalkenyl
Prior art date
Application number
MX2009002707A
Other languages
Spanish (es)
Inventor
Jeffrey B Arterburn
Coleen B Jonsson
William B Parker
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of MX2009002707A publication Critical patent/MX2009002707A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Azole nucleosides represented by the formulae (I) and (II); wherein A = C or N B = C or N X = H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, C1, Br and I; OH, NH2, NH-(C1-C6 alkyl, cycloalkyl, aryl, or heterocyclo); Z = H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br, I; OH, NH2, NH-(C1-C6 alkyl, cycloalkyl, aryl, or heterocyclo; E= (CH2)HONHR1; n is an integer from 0-6 and more typically 0-3; R1= aryl or heterocyclo; each of W, Y, R is individually selected from the group consisting of H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo; halogen such as F, Cl, Br, and I; O, OH, Oalkyl, Oaryl, NH2, NH-(C1-C6 alkyl, cycloalkyl, aryl, or heterocyclo); provided that at least one of W, Y, and R is other than H and wherein both W and Y together can be =O; and each D individually is OH, Oalkyl, Oaryl, Fl and H;pharmaceutically acceptable salts thereof, prodrugs thereof and mixtures thereof are provided. Compounds of this disclosure are useful as inhibitors of viral RNA and DNA polymerases such as, but not limited to, Influenza, Hantaan Virus, Crimean Congo hemorrhagic fever virus, hepatitis B, hepatitis C, Polio, Coxsackie A and B, Rhino, Echo, orthopoxvirus (small pox), HIV, Ebola, and West Nile virus polymerases; and especially orthopoxvirus, HIV, and hepatitis B.
MX2009002707A 2006-09-11 2007-09-11 Azole nucleosides and use as inhibitors of rna and dna varial polymerases. MX2009002707A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84339806P 2006-09-11 2006-09-11
PCT/US2007/078139 WO2008067002A2 (en) 2006-09-11 2007-09-11 Azole nucleosides and use as inhibitors of rna and dna varial polymerases

Publications (1)

Publication Number Publication Date
MX2009002707A true MX2009002707A (en) 2009-11-26

Family

ID=39468551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002707A MX2009002707A (en) 2006-09-11 2007-09-11 Azole nucleosides and use as inhibitors of rna and dna varial polymerases.

Country Status (11)

Country Link
US (1) US20100129317A1 (en)
EP (1) EP2061316A4 (en)
JP (1) JP2010502748A (en)
KR (1) KR20090094800A (en)
CN (1) CN101511185A (en)
AU (1) AU2007325551A1 (en)
CA (1) CA2663618A1 (en)
EA (1) EA016830B1 (en)
IL (1) IL197415A0 (en)
MX (1) MX2009002707A (en)
WO (1) WO2008067002A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0714649D0 (en) * 2007-07-27 2007-09-05 Univ Leuven Kath Novel viral replication inhibitors
EP2113508A1 (en) * 2008-04-30 2009-11-04 INSERM (Institut National de la Santé et de la Recherche Medicale) Novel triazole nucleoside derivatives, their preparation and their application in therapeutics
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
RS56870B1 (en) 2010-10-15 2018-04-30 Biocryst Pharm Inc Pyrrolopyrimidine derivatives for use in the treatment of viral infections
AR090699A1 (en) 2012-04-18 2014-12-03 Biocryst Pharm Inc INHIBITING COMPOUNDS OF VIRAL POLYMERASE RNA ACTIVITY
CA3016588A1 (en) 2016-03-06 2017-09-14 Biocryst Pharmaceuticals, Inc. Methods and compositions for treatment of zika virus infection

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968103A (en) * 1972-09-28 1976-07-06 Icn Pharmaceuticals, Inc. 1,2,3-Triazole nucleosides
JPS6426593A (en) * 1987-07-21 1989-01-27 Asahi Glass Co Ltd Nucleoside derivative
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
US4992426A (en) * 1989-02-27 1991-02-12 Nucleic Acid Research Institute Antiparasitic 5'-sulfamoyl nucleosides
US6358931B1 (en) * 1990-01-11 2002-03-19 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA
US7037646B1 (en) * 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6060592A (en) * 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US6339066B1 (en) * 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6783931B1 (en) * 1990-01-11 2004-08-31 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
US6262241B1 (en) * 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
CA2133355A1 (en) * 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
GB9602028D0 (en) * 1996-02-01 1996-04-03 Amersham Int Plc Nucleoside analogues
IL129126A0 (en) * 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
EP1244356A4 (en) * 1999-12-23 2003-03-19 Icn Pharmaceuticals Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
US6495677B1 (en) * 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
FR2810322B1 (en) * 2000-06-14 2006-11-10 Pasteur Institut COMBINATORY PRODUCTION OF NUCLEOTIDE AND NUCLEOTIDE ANALOGUES (XiTP)
US6900298B2 (en) * 2002-02-12 2005-05-31 Mitsubishi Chemical Corporation Process for producing nucleic acid derivative
CA2477795A1 (en) * 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
CA2537849A1 (en) * 2003-09-11 2005-03-17 F. Hoffmann-La Roche Ag Process for preparing antiviral nucleoside derivatives
US7348146B2 (en) * 2003-10-02 2008-03-25 Epoch Biosciences, Inc. Single nucleotide polymorphism analysis of highly polymorphic target sequences

Also Published As

Publication number Publication date
WO2008067002A3 (en) 2008-11-06
WO2008067002A2 (en) 2008-06-05
KR20090094800A (en) 2009-09-08
WO2008067002A8 (en) 2008-09-12
CN101511185A (en) 2009-08-19
EP2061316A2 (en) 2009-05-27
JP2010502748A (en) 2010-01-28
CA2663618A1 (en) 2008-06-05
AU2007325551A1 (en) 2008-06-05
EA200970261A1 (en) 2010-02-26
IL197415A0 (en) 2009-12-24
US20100129317A1 (en) 2010-05-27
EP2061316A4 (en) 2011-08-24
EA016830B1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
MX2009002707A (en) Azole nucleosides and use as inhibitors of rna and dna varial polymerases.
EA201100850A1 (en) PHOSPHORAMIDATES OF NUCLEOSIDES
MX2009004888A (en) Hepatitis c virus inhibitors.
NZ526703A (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GT200200117A (en) NUCLEOSIDE DERIVATIVES
NZ593649A (en) Nucleoside analogs
UA91255C2 (en) Antiviral nucleosides
TW200720285A (en) Nucleoside compounds for treating viral infections
HK1128131A1 (en) Hepatitis c virus inhibitors
EA201000948A1 (en) VIRAL POLYMERASE INHIBITORS
MD4403C1 (en) Antiviral compounds based on condensed dihydroxyisochromene-naphthoimidazoles
GB0718575D0 (en) Nucleoside derivatives as inhibitors of viral polymerases
MX2010002904A (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors.
HRP20070078A2 (en) Nucleoside phosphonate conjugates as anti hiv agents
MX2008010611A (en) 3 -deazapurine derivatives as tlr7 modulators.
PH12013500365A1 (en) Anti-infective agents and uses thereof
MX2010002902A (en) Anti-infective pyrimidines and uses thereof.
EP2120565A4 (en) Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
CO6270240A2 (en) Double-stranded RNA with modified lipid that has a powerful RNA interference effect
WO2008008776A3 (en) Hepatitis c virus inhibitors
CL2011001364A1 (en) Compounds derived from cyclopropyl uracil nucleotides, hepatitis c virus polymerase inhibitors; pharmaceutical compositions; and use of the compound for the treatment of hepatitis c (hcv).
UY32119A (en) CRYSTAL FORMS OF A POWERFUL HCV INHIBITOR
CY1114932T1 (en) ANTIPARASSIAN FACTORS
WO2009073506A3 (en) Nucleoside prodrugs and uses thereof
NZ631182A (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal